Randomized trial evaluating the impact of ribavirin mono-therapy and double dosing on viral kinetics, ribavirin pharmacokinetics and anemia in hepatitis C virus genotype 1 infection
(2016) In PLoS ONE 11(5).- Abstract
In this pilot study (RibaC), 58 hepatitis C virus (HCV) genotype 1 infected treatment-naïve patients were randomized to (i) 2 weeks ribavirin double dosing concomitant with pegylated interferon-α (pegIFN-α), (ii) 4 weeks ribavirin mono-therapy prior to adding pegIFN-α, or (iii) standard-of-care (SOC) ribavirin dosing concurrent with pegIFN-α. Four weeks of ribavirin mono-therapy resulted in a mean 0.46 log10 IU/mL HCV RNA reduction differentially regulated across IL28B genotypes (0.89 vs. 0.21 log10 IU/mL for CC and CT/TT respectively; P = 0.006), increased likelihood of undetectable HCV RNA week 4 after initiating pegIFN-α and thus shortened treatment duration (P
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8f34c092-de60-485e-96e2-70ee0cf965e1
- author
- organization
- publishing date
- 2016
- type
- Contribution to journal
- publication status
- published
- subject
- in
- PLoS ONE
- volume
- 11
- issue
- 5
- article number
- e0155142
- publisher
- Public Library of Science (PLoS)
- external identifiers
-
- pmid:27167219
- wos:000376587300084
- scopus:84969796323
- ISSN
- 1932-6203
- DOI
- 10.1371/journal.pone.0155142
- language
- English
- LU publication?
- yes
- id
- 8f34c092-de60-485e-96e2-70ee0cf965e1
- date added to LUP
- 2016-06-14 12:39:06
- date last changed
- 2024-04-05 02:04:17
@article{8f34c092-de60-485e-96e2-70ee0cf965e1, abstract = {{<p>In this pilot study (RibaC), 58 hepatitis C virus (HCV) genotype 1 infected treatment-naïve patients were randomized to (i) 2 weeks ribavirin double dosing concomitant with pegylated interferon-α (pegIFN-α), (ii) 4 weeks ribavirin mono-therapy prior to adding pegIFN-α, or (iii) standard-of-care (SOC) ribavirin dosing concurrent with pegIFN-α. Four weeks of ribavirin mono-therapy resulted in a mean 0.46 log<sub>10</sub> IU/mL HCV RNA reduction differentially regulated across IL28B genotypes (0.89 vs. 0.21 log<sub>10</sub> IU/mL for CC and CT/TT respectively; P = 0.006), increased likelihood of undetectable HCV RNA week 4 after initiating pegIFN-α and thus shortened treatment duration (P</p>}}, author = {{Waldenström, Jesper and Westin, Johan and Nyström, Kristina and Christensen, Peer and Dalgard, Olav and Färkkilä, Martti and Lindahl, Karin and Nilsson, Staffan and Norkrans, Gunnar and Krarup, Henrik and Norrgren, Hans and Buhl, Mads Rauning and Stenmark, Stephan and Lagging, Martin}}, issn = {{1932-6203}}, language = {{eng}}, number = {{5}}, publisher = {{Public Library of Science (PLoS)}}, series = {{PLoS ONE}}, title = {{Randomized trial evaluating the impact of ribavirin mono-therapy and double dosing on viral kinetics, ribavirin pharmacokinetics and anemia in hepatitis C virus genotype 1 infection}}, url = {{http://dx.doi.org/10.1371/journal.pone.0155142}}, doi = {{10.1371/journal.pone.0155142}}, volume = {{11}}, year = {{2016}}, }